11.89MMarket Cap-750P/E (TTM)
1.9500High1.9500Low1.73KVolume1.9500Open1.9500Pre Close3.37KTurnover0.03%Turnover RatioLossP/E (Static)6.10MShares4.690052wk High4.79P/B11.89MFloat Cap1.810052wk Low--Dividend TTM6.10MShs Float1419.0000Historical High--Div YieldTTM0.00%Amplitude1.5200Historical Low1.9500Avg Price1Lot Size
Can-Fite BioPharma Stock Forum
6 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology firm dedicated to developing innovative treatments for oncological and inflammatory diseases, has unveiled new findings concerning its small molecule drug, Namodenoson. These recent discoveries shed light on the mechanisms by which Namodeno...
Rhe FDA Has Granted Investigational New Drug Clearance For Can-Fite Biopharma's Namodenoson, For Metabolic Dysfunction-Associated Steatohepatitis, Also Known As Non-alcoholic Steatohepatitis, For The Company's Ongoing Phase 2B Study
NEWS
Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602
Moomoo 24/7· 1 min ago
No comment yet